In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerat...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_incontextgauss_IBG_A131712699

In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo; -- Novel Monoclonal Antibody Was Well Tolerated In Ulcerative Colitis And Crohn's Disease Studies

About this item

Full title

In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo; -- Novel Monoclonal Antibody Was Well Tolerated In Ulcerative Colitis And Crohn's Disease Studies

Publisher

PR Newswire Association LLC

Journal title

PR newswire, 2003-05-21

Language

English

Formats

Newspaper Articles

Publication information

Publisher

PR Newswire Association LLC

Subjects

Subjects and topics

More information

Alternative Titles

Full title

In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo; -- Novel Monoclonal Antibody Was Well Tolerated In Ulcerative Colitis And Crohn's Disease Studies

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_incontextgauss_IBG_A131712699

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_incontextgauss_IBG_A131712699

How to access this item

Log in as a Library member

View record in Gale

View in old catalogue

Connecting people and collections

Indigenous engagement

Celebrating and sharing stories of Indigenous Australia, and helping to locate and prioritise Indigenous voices in the Library's collections.

Schools and teachers

Learning programs and resources linked to the curriculum.

Stories

Showcasing people, places and ideas inspired by the collection and the library community.